Richard M. Glickman's Insider Trades & SAST Disclosures
Richard M. Glickman's most recent trade in enGene Holdings Inc was a trade of 20,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 15, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Richard M. Glickman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| enGene Holdings Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2024 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| enGene Holdings Inc | Richard M. Glickman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.89 per share. | 28 May 2024 | 120 | 24,675 | - | 0.9 | 107 | Common Shares |
| enGene Holdings Inc | Richard M. Glickman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2024 | 120 | 0 | - | - | Stock Option (Right to Buy) | |
| Essa Pharma Inc | Richard M. Glickman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2024 | 3,750 | 0 | - | - | Options | |
| Essa Pharma Inc | Richard M. Glickman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.90 per share. | 24 Apr 2024 | 3,750 | 43,240 (0%) | 0% | 4.9 | 18,375 | Common Shares |
| Essa Pharma Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 70,000 | 70,000 | - | - | Options | |
| enGene Holdings Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2023 | 24,555 | 24,555 | - | - | Common Shares | |
| enGene Holdings Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2023 | 14,205 | 14,205 | - | - | Stock Option (Right to Buy) | |
| enGene Holdings Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2023 | 12,032 | 12,032 | - | - | Stock Option (Right to Buy) | |
| enGene Holdings Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2023 | 12,001 | 12,001 | - | - | Stock Option (Right to Buy) | |
| enGene Holdings Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2023 | 11,189 | 11,189 | - | - | Stock Option (Right to Buy) | |
| enGene Holdings Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2023 | 9,023 | 9,023 | - | - | Stock Option (Right to Buy) | |
| enGene Holdings Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2023 | 4,123 | 4,123 | - | - | Stock Option (Right to Buy) | |
| enGene Holdings Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2023 | 3,188 | 3,188 | - | - | Stock Option (Right to Buy) | |
| enGene Holdings Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2023 | 120 | 120 | - | - | Stock Option (Right to Buy) | |
| Essa Pharma Inc | Richard M. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges